THE PHENOPTOSIS CONCEPT AND SYSTEMIC APPROACH IN NEPHROLOGY
https://doi.org/10.24884/1561-6274-2013-17-5-16-21
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Stable existence of complex self-organizing systems is supported by a network of feedback that submit information from the “output” of the system to its control elements. From the cybernetic point of view the excretory system is a “way out” of human metabolic network. Therefore, nephrological aspects of systemic medicine require a special attention. According to the concept of phenoptosis, effective existence of biological communities is often supported by mechanisms of weakening or destroy of individuals. Systemic manifestation of phenoptosis mechanisms is an age related increase of frequency and severity of abnormalities, including kidney diseases. A key element of most phenoptosis processes is increased generation of reactive oxygen species by mitochondria. Using of mitochondria-targeted antioxidants (Skulachev ions with antioxidant load - SkQ) allows to “turn off” such mechanisms, reducing mitochondrial oxidative stress. At the same time the course of acute renal injury induced by acute ischemia improves. Mortality of laboratory animals significantly decreases. For future clinical trials of SkQ oral dosage forms a systemic therapeutic effect in the treatment of renal disease could be expected.
About the Authors
V. A. Chistyakov
Ростовский государственный медицинский университет; Научноисследовательский институт биологии Южного федерального университета
Russian Federation
Russian Federation
D. S. Tsvetkov
Ростовский государственный медицинский университет
Russian Federation
Russian Federation
E. V. Prazdnova
Научноисследовательский институт биологии Южного федерального университета
Russian Federation
Russian Federation
I. B. Chistyakova
Научноисследовательский институт биологии Южного федерального университета
Russian Federation
Russian Federation
References
1. von Bertalanffy L. The Theory of Open Systems in Physics and Biology. Science, 1950; 111 (2872): 23-29
2. von Bertalanffy L. General system theory, a new approach to unity of science. 6. Towards a physical theory of organic teleology, feedback and dynamics. Hum Biol. 1951; 23(4):346-361
3. Jacob F, Monod J. Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol. 1961; 3:318-356
4. Dil'man VM. Bol'shie biologicheskie chasy (vvedenie v integral'nuyu meditsinu). Znanie, M., 1982; 208 s
5. Dilman VM. Three models of medicine. (An integrated theory of aging and age-associated diseases). Med Hypotheses. 1984; 15(2):185-208
6. Dilman VM. Four models of medicine: mechanisms of aging and conditions promoting cancer development. Ann N Y Acad Sci. 1988; 521:226-7
7. von Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensinconverting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensinaldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16):2088-2097
8. Skulachev VP. Starenie organizma osobaya biologicheskaya funktsiya, a ne rezul'tat polomki slozhnoi zhivoi sistemy: biokhimicheskoe obosnovanie kontseptsii Veismana. Biokhimiya. 1997; 62 (11): S. 1369 - 1399
9. Skulachev VP. Popytka biokhimikov atakovat' problemu stareniya: «Megaproekt» po pronikayushchim ionam. Pervye itogi i perspektivy. Biokhimiya. 2007; 72(12): 1572 - 1586.
10. Skulachev VP. Kak otmenit' programmu stareniya tela? Zhurnal obshchei khimii. 2010. 80(7): 1523-1541
11. Skulachev VP. Chto takoe «fenoptoz» i kak s nim borot'sya? Biokhimiya. 2012; 77(7): 827-846
12. Skulachev VP. Aging as a particular case of phenoptosis, the programmed death of an organism (a response to Kirkwood and Melov «On the programmed/non-programmed nature of ageing within the life history»). Aging (Albany NY). 2011; 3(11):1120-1123
13. Libertini Dzh. Klassifikatsiya yavlenii fenoptoza. Biokhimiya. 2012; 77(7):707-715
14. Mittel'dorf Dzh.Dzh. Adaptivnoe starenie k kontekste evolyutsionnoi teorii. Biokhimiya. 2012; 77(7):716-25.
15. Goldsmit T.K. O protivorechiyakh teorii zaprogrammirovannogo i nezaprogrammirovannogo stareniya: obzor. Biokhimiya. 2012; 77(7):729-732
16. Skulachev V.P. In Model Systems in Aging (Nystrom, T., and Osiewacz, HD, eds), Springer_Verlag, Berlin, Heidelberg, 2003; 191-238
17. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol 1956; 11 (3), 298-300
18. Scilard L. On the nature of the aging process. Proc. nat Acad. Sci. USA. 1959; 45:30-45
19. Antonenko YuN, Avetisyan AV, Bakeeva LE i dr. Proizvodnoe plastokhinona, adresovannoe v mitokhondrii, kak sredstvo, preryvayushchee programmu stareniya. Kationnye proizvodnye plastokhinona: sintez i issledovanie in vitro. Biokhimiya. 2008; 73 (12):1273-1287
20. Severin FF, Severina II, Antonenko YN et al. Penetrating cation/fatty acid anion pair as a mitochondria-targeted protonophore. Proc Natl Acad Sci USA. 2010; 107(2):663-668
21. Anisimov VN, Egorov MV, Krasilshchikova MS et al. Effects of the mitochondria-targeted antioxidant SkQ1 on lifespan of rodents. Aging (Albany NY). 2011; 3(11):1110-1119
22. Skulachev M. et al. Mitochondrial-targeted plastoquinone derivatives. Effect on senescence and acute age-related pathologies. Curr Drug Targets. 2011; 12(6):800-826
23. Saprunova VB, Lelekova MA, Kolosova NG, Bakeeva LE. SkQ1 zamedlyaet razvitie zavisimykh ot vozrasta destruktivnykh protsessov v setchatke i sosudistom sloe glaz Wistar i OXYS. Biokhimiya. 2012; 77(6):796-808
24. Yani EV, Katargina LA, Chesnokova NB i dr. Pervyi opyt ispol'zovaniya preparata «Vizomitin» v terapii «sukhogo glaza». Prakticheskaya meditsina. 2012; 1 (59): 134-137
25. Srisawat N, Hoste EE, Kellum J.A. Modern classification of acute kidney injury. Blood Purif 2010; 29: 300-307
26. Go AS, Chertow GM, Fan D et al. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med 2004; 351:1296-1305
27. Keith DS, Nichols GA, Gullion CM et al. Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization. Arch Intern Med 2004; 164: 659-663
28. Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:251-262
29. Palmer SC, Craig JC, Navaneethan SD. et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:263-275
30. Hill G.S. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 2008; 7(3):266-270
31. Stanton R.C. Oxidative stress and diabetic kidney disease. Curr Diab Rep 2011; 11(4):330-336
32. Djamali A. Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol Renal Physiol 2007; 293(2):445-455
33. Swaminathan S, Shah SV. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17(2):143-148
34. Bakeeva LE, Barskov IV, Egorov MV. Proizvodnoe plastokhinona, adresovannoe v mitokhondrii, kak sredstvo, preryvayushchee programmu stareniya. Terapiya nekotorykh starcheskikh patologii, oposredovannykh AFK (serdechnoi aritmii, infarktov serdtsa i pochki i insul'ta golovnogo mozga). Biokhimiya 2008; 73(12):1288-1299
35. Zorov DV, Plotnikov EI i dr. Fenoptoznaya problema: ot chego gibnet organizm? Uroki po pechenochnoi nedostatochnosti. Biokhimiya 2012;77(7):742-753
Review
For citations:
Chistyakov V.A., Tsvetkov D.S., Prazdnova E.V., Chistyakova I.B. THE PHENOPTOSIS CONCEPT AND SYSTEMIC APPROACH IN NEPHROLOGY. Nephrology (Saint-Petersburg). 2013;17(5):16-21. (In Russ.) https://doi.org/10.24884/1561-6274-2013-17-5-16-21
Views:
383
ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)
ISSN 2541-9439 (Online)
Email this article 